- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 1, 2024Robins Kaplan Recognized for “Tipping the Scales” by Diversity & Flexibility Alliance
-
October 28, 2024Philip Sieff Honored with Minnesota Icon Award
-
October 24, 2024Mid-Minnesota Legal Aid, Robins Kaplan Bring Class Action Suit Against Mobile Home Park
-
November 7, 2024Building Your Legal Brand in a Digital World
-
November 7, 2024Financial Literacy for Associates
-
November 7, 2024Structuring IP Finance Deals That Work
-
September 2024Meet Our New Partner and Trial Advocacy Seminar Keynote Speaker: B. Todd Jones
-
September 18, 2024Astellas Pharma, Inc. v. Sandoz Inc.
-
September 2024Q&A with Alan Harter, Founder of Pactolus Private Wealth Management
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc.
Tirosint®/levothyroxine sodium
July 31, 2020
Case Name: IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc., No. 2019-2400 (Fed. Cir. July 31, 2020) (Circuit Judges Prost, Reyna, and Hughes presiding; Opinion by Prost, C.J.) (Appeal from D. Del., Andrews, J.)
Drug Product and Patent(s)-in-Suit: Tirosint® (levothyroxine sodium); U.S. Pat. No. 7,723,390 (“the ’390 Patent”)
Nature of the Case and Issue(s) Presented: The ’390 patent claimed pharmaceutical formulations used to treat thyroid disorders. The parties’ primary dispute was the claim construction of “half-liquid.” The intrinsic record did not define “half-liquid.” IBSA argued that this term meant “semi-liquid, i.e., having a thick consistency between solid and liquid.” Teva argued that the term was indefinite, or, in the alternative, that it should be construed as “a non-solid, non-paste, non-gel, non-slurry, non-gas substance.”
IBSA presented evidence that an earlier Italian Application used the term “semiliquido” in the same places that the ’390 patent used “half-liquid,” indicating that a POSITA would understand “half-liquid” and “semi-liquid” to be synonyms. But the district court explained that there were a number of differences between the certified translation and the ’390 patent specification and gave no weight to that document. The district court also noted that, during prosecution, the applicant proposed a dependent claim using the term “semi-liquid,” which depended from an independent claim that recited a “half-liquid.” As to the extrinsic record, the district court found that IBSA failed to present evidence that the term “half-liquid” was known in the art.
The district court next attempted to determine whether a skilled artisan could nevertheless ascertain a reasonably certain meaning for “half-liquid.” Based on the claim language, the district court noted that “half-liquid” was neither a liquid nor a solid. Further, reading the specification, a POSITA would have understood that a “half-liquid” was not, or at least was not necessarily, a gel or a paste. And after reviewing the prosecution history, the district court determined that the applicant disclaimed some portion of the claim’s scope that might have otherwise qualified as a half-liquid. In the end, the district court determined that ambiguity rendered it impossible for a POSITA to know, with reasonable certainty, the scope of the term “half-liquid” and found the ‘390 patent invalid as indefinite. The Federal Circuit affirmed.
Why Teva Prevailed: The Federal Circuit noted that the claim language did not make “half-liquid” reasonably clear. It next looked to the specification and concluded that the passage explaining that “said soft capsule contains an inner phase consisting of a liquid, a half-liquid, a paste, a gel, an emulsion or a suspension comprising the liquid (or half-liquid) vehicle and the thyroid hormones together with possible excipients in suspension or solution” provided no greater clarity. As to the prosecution history, the Federal Circuit agreed with Teva’s conclusion that a POSITA would consider the different usage of “half liquid” and “semiliquido” in the Italian Application to be intentional, indicating that the different words had different scopes.
Related Professionals
Christopher A. Pinahs
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.